Shandong Hehua Biotechnology Co., Ltd.

As of February 13, a total of 257 biopharmaceutical companies have disclosed their performance forecasts for 2024, with over 50 firms expecting to see their net profits double. Notably, companies such as North China Pharmaceutical, Zhejiang Medicine, Darentang, Huilong Pharmaceutical, and Sanofi are among those predicting substantial increases. Among these, North China Pharmaceutical anticipates that its net profit attributable to shareholders will reach approximately 125 million yuan, reflecting a staggering 2456.08% year-on-year growth. The company attributes this remarkable performance to strategic adjustments in product structure, enhanced procurement management, and effective cost control measures. Hehua Co. is also forecasting impressive results, with expected revenues between 190 million and 250 million yuan and a net profit of 78 million to 86 million yuan, marking a 774.79% to 844% increase. The firm has benefited from transferring its urea production capacity, resulting in significant non-operating income. Microelectrophysiology projects a net profit between 47 million and 56 million yuan, indicating a remarkable increase of 726.23% to 884.44%. The company’s growth stems from enhanced market strategies and the successful expansion of its high-value product lines, including the TrueForce® pressure monitoring catheter. Haizheng Pharmaceutical estimates a net profit in the range of 570 million to 630 million yuan, reflecting a 711.78% to 776.17% increase, driven by strong product growth and operational efficiencies. These figures underscore the evolving landscape of the biopharmaceutical industry, as companies adapt and thrive amid changing market conditions. With innovative strategies and products, these firms are well-positioned for a prosperous year ahead.